<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2022-11-2-169-173</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1231</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ И КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL AND CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Модуляция активности rage и CD147 при церебральной амилоидной ангиопатии in vitro</article-title><trans-title-group xml:lang="en"><trans-title>Modulation of Rage and CD147 in Cerebral Amyloid Angiopathy in vitro</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7344-7925</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мосягина</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Mosiagina</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>660022, г. Красноярск, ул. Партизана Железняка, д. 1</p></bio><bio xml:lang="en"><p>1, Partizana Zheleznyaka str., Krasnoyarsk, 660022</p></bio><email xlink:type="simple">angelina.mosiagina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойцова</surname><given-names>Е. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Boytsova</surname><given-names>E. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>660022, г. Красноярск, ул. Партизана Железняка, д. 3а</p></bio><bio xml:lang="en"><p>3a, Partizana Zheleznyaka str., Krasnoyarsk, 660022</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9718-1260</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хилажева</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Khilazheva</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>660022, г. Красноярск, ул. Партизана Железняка, д. 1</p></bio><bio xml:lang="en"><p>1, Partizana Zheleznyaka str., Krasnoyarsk, 660022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7544-3779</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тепляшина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Teplyashina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>660022, г. Красноярск, ул. Партизана Железняка, д. 1</p></bio><bio xml:lang="en"><p>1, Partizana Zheleznyaka str., Krasnoyarsk, 660022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9644-5500</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моргун</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Morgun</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>660022, г. Красноярск, ул. Партизана Железняка, д. 1</p></bio><bio xml:lang="en"><p>1, Partizana Zheleznyaka str., Krasnoyarsk, 660022</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4012-6348</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Салмина</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Salmina</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>660022, г. Красноярск, ул. Партизана Железняка, д. 1; 125367, г. Москва, Волоколамское шоссе, д. 80</p></bio><bio xml:lang="en"><p>1, Partizana Zheleznyaka str., Krasnoyarsk, 660022; 80, Volokolamskoye shosse, Moscow, 125367</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В. Ф. Войно-Ясенецкого» Минздрава России</institution></aff><aff xml:lang="en"><institution>Professor V. F. Voino-Yasenetsky Krasnoyarsk State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Красноярское государственное бюджетное учреждение здравоохранения «Краевая клиническая больница»</institution></aff><aff xml:lang="en"><institution>Regional Government-Owned Publicly Funded Healthcare Institution "Regional Clinical Hospital"</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В. Ф. Войно-Ясенецкого» Минздрава России; ФГБНУ «Научный центр неврологии»</institution></aff><aff xml:lang="en"><institution>Professor V. F. Voino-Yasenetsky Krasnoyarsk State Medical University; Brain Research Department, Scientific Center of Neurology</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>30</day><month>05</month><year>2022</year></pub-date><volume>11</volume><issue>2</issue><fpage>169</fpage><lpage>173</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мосягина А.И., Бойцова Е.Б., Хилажева Е.Д., Тепляшина Е.А., Моргун А.В., Салмина А.Б., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Мосягина А.И., Бойцова Е.Б., Хилажева Е.Д., Тепляшина Е.А., Моргун А.В., Салмина А.Б.</copyright-holder><copyright-holder xml:lang="en">Mosiagina A.I., Boytsova E.B., Khilazheva E.D., Teplyashina E.A., Morgun A.V., Salmina A.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1231">https://www.pharmjournal.ru/jour/article/view/1231</self-uri><abstract><sec><title>Введение</title><p>Введение. В рамках изучения болезни Альцгеймера (БА) все большую актуальность приобретает проблема причинно-следственной связи между нейродегенеративными изменениями и сопровождающей их амилоидной ангиопатией. Накопленный багаж клинических данных указывает на то, что в патогенез БА важный вклад вносят нарушения со стороны нейроваскулярной единицы, в том числе нарушения проницаемости гематоэнцефалического барьера (ГЭБ), микроциркуляции, метаболического сопряжения клеток.</p></sec><sec><title>Цель</title><p>Цель. Изучение молекулярных механизмов нарушения церебральной микроциркуляции и структурно-функциональной целостности ГЭБ в экспериментальных моделях БА in vitro при модуляции активности CD147 и RAGE.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование провели на мышах линии C57BL/6 с формированием у животных модели БА in vivo. Далее произвели изоляцию и культивирование первичных клеток головного мозга, модуляцию активности CD147 и RAGE в клетках эндотелия in vitro с помощью siRNA CD147, siRNA RAGE, циклофилина А и Aβ1-42 и cформировали модель ГЭБ in vitro. В модели ГЭБ in vitro оценили трансэндотелиальное электрическое сопротивление. В культурах эндотелиальных клеток оценили относительное количество молекул-маркеров ангиогенеза и экспрессию гена APP. Статистическую обработку полученных результатов провели методами непараметрической статистики с помощью критерия Манна – Уитни для сравнения показателей в независимых выборках и с помощью критерия Уилкоксона для сравнения зависимых выборок. Уровень статистической значимости различий p ≤ 0,05.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Блокирование экспрессии RAGE привело к статистически значимому увеличению показателей ТЭС, интенсификации ангиогенеза и снижению уровня экспрессии APP. Одновременно с этим, блокирование CD147 хотя и привело к увеличению показателей ТЭС, но также характеризовалось противоречивым действием на неоангиогенез и увеличением экспрессии APP.</p></sec><sec><title>Заключение</title><p>Заключение. Анализируя полученные данные, можно сделать вывод, что подавление экспрессии RAGE и CD147 в клетках церебральных микрососудов может стать перспективным методом снижения их патологической проницаемости.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. In the study of Alzheimer’s disease (AD), the cause-and-effect relationship between neurodegenerative changes and the accompanying amyloid angiopathy is becoming increasingly important. The accumulated clinical data indicates that an important contribution to the pathogenesis of AD is made by neurovascular unit dysfunction, including disruption in permeability of the blood-brain barrier (BBB), microcirculation, and metabolic coupling of cells.</p></sec><sec><title>Aim</title><p>Aim. To study the molecular mechanisms of disturbed brain microcirculation and the structural and functional integrity of the BBB in experimental models of AD in vitro under the modulation of CD147 and RAGE.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study was carried out on C57BL/6 mice. First, we formed an AD model in animals of the experimental group. Then, we isolated and cultured primary cells of the brain, modulated the activity of CD147 and RAGE in endothelial cells using siRNA CD147, siRNA RAGE, cyclophilin A and Aβ1-42, and formed a BBB model in vitro. Further, we assessed transendothelial electrical resistance in the BBB model in vitro, registered the marker molecules of angiogenesis and analyzed the expression of APP in endothelial cells. Statistical processing of the obtained data was carried out using the methods of nonparametric statistics: the Mann – Whitney U test for comparing independent samples and the Wilcoxon test for comparing dependent samples. The level of statistical significance of differences was p ≤ 0.05.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Knockdown of RAGE led to a statistically significant increase in TEER, an intensification of neoangiogenesis, and a decrease in the level of APP expression. At the same time, although CD147 knockdown led to an increase in TEER, it also led to controversial effects on angiogenesis and an increase in APP expression.</p></sec><sec><title>Conclusion</title><p>Conclusion. Analyzing the data obtained, it can be concluded that RAGE and CD147 silencing in the cells of cerebral microvessels can become a promising method for reducing their pathological permeability.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>CD147</kwd><kwd>RAGE</kwd><kwd>болезнь Альцгеймера</kwd><kwd>амилоидная ангиопатия</kwd><kwd>нейроваскулярная единица</kwd><kwd>гематоэнцефалический барьер</kwd></kwd-group><kwd-group xml:lang="en"><kwd>CD147</kwd><kwd>RAGE</kwd><kwd>Alzheimer’s disease</kwd><kwd>amyloid angiopathy</kwd><kwd>neurovascular unit</kwd><kwd>blood-brain barrier</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Langen U. H., Ayloo S., Gu C. Development and Cell Biology of the Blood-Brain Barrier. Annual Review of Cell and Developmental Biology. 2019;35:591–613. DOI: 10.1146/annurev-cellbio-100617-062608.</mixed-citation><mixed-citation xml:lang="en">Langen U. H., Ayloo S., Gu C. Development and Cell Biology of the Blood-Brain Barrier. Annual Review of Cell and Developmental Biology. 2019;35:591–613. DOI: 10.1146/annurev-cellbio-100617-062608.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Iadecola C. The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron. 2017;96(1):17–42. DOI: 10.1016/j.neuron.2017.07.030.</mixed-citation><mixed-citation xml:lang="en">Iadecola C. The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron. 2017;96(1):17–42. DOI: 10.1016/j.neuron.2017.07.030.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gallardo G., Holtzman D. M. Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease. Advances in Experimental Medicine and Biology. 2019;1184:187–203. DOI: 10.1007/978-981-32-9358-8_16.</mixed-citation><mixed-citation xml:lang="en">Gallardo G., Holtzman D. M. Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease. Advances in Experimental Medicine and Biology. 2019;1184:187–203. DOI: 10.1007/978-981-32-9358-8_16.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Graham W. V., Bonito-Oliva A., Sakmar T. P. Update on Alzheimer’s Disease Therapy and Prevention Strategies. Annual Review of Medicine. 2017;68:413–430. DOI: 10.1146/annurev-med-042915-103753.</mixed-citation><mixed-citation xml:lang="en">Graham W. V., Bonito-Oliva A., Sakmar T. P. Update on Alzheimer’s Disease Therapy and Prevention Strategies. Annual Review of Medicine. 2017;68:413–430. DOI: 10.1146/annurev-med-042915-103753.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kisler K., Nelson A. R., Montagne A., Zlokovic B. V. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nature Reviews Neuroscience. 2017;18(7):419–434. DOI: 10.1038/nrn.2017.48.</mixed-citation><mixed-citation xml:lang="en">Kisler K., Nelson A. R., Montagne A., Zlokovic B. V. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nature Reviews Neuroscience. 2017;18(7):419–434. DOI: 10.1038/nrn.2017.48.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yamazaki Y., Kanekiyo T. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease. International Journal of Molecular Sciences. 2017;18(9):1965. DOI: 10.3390/ijms18091965.</mixed-citation><mixed-citation xml:lang="en">Yamazaki Y., Kanekiyo T. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease. International Journal of Molecular Sciences. 2017;18(9):1965. DOI: 10.3390/ijms18091965.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X., Hou D., Lin F., Luo J., Xie J., Wang Y., Tian Y. The role of neurovascular unit damage in the occurrence and development of Alzheimer’s disease. Reviews in the Neurosciences. 2019;30(5):477–484. DOI: 10.1515/revneuro-2018-0056.</mixed-citation><mixed-citation xml:lang="en">Liu X., Hou D., Lin F., Luo J., Xie J., Wang Y., Tian Y. The role of neurovascular unit damage in the occurrence and development of Alzheimer’s disease. Reviews in the Neurosciences. 2019;30(5):477–484. DOI: 10.1515/revneuro-2018-0056.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Iturria-Medina Y., Sotero R. C., Toussaint P. J., Mateos-Pérez J. M., Evans A. C. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nature Communications. 2016;7:11934. DOI: 10.1038/ncomms11934.</mixed-citation><mixed-citation xml:lang="en">Iturria-Medina Y., Sotero R. C., Toussaint P. J., Mateos-Pérez J. M., Evans A. C. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nature Communications. 2016;7:11934. DOI: 10.1038/ncomms11934.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cisternas P., Taylor X., Lasagna-Reeves C. A. The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy. International Journal of Molecular Sciences. 2019;20(24):6319. DOI: 10.3390/ijms20246319.</mixed-citation><mixed-citation xml:lang="en">Cisternas P., Taylor X., Lasagna-Reeves C. A. The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy. International Journal of Molecular Sciences. 2019;20(24):6319. DOI: 10.3390/ijms20246319.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H., Lv J. J., Zhao Y., Wei H. L., Zhang T. J., Yang H. J., Chen Z. N., Jiang J. L. Endothelial genetic deletion of CD147 induces changes in the dual function of the blood-brain barrier and is implicated in Alzheimer’s disease. CNS Neuroscience &amp; Therapeutics. 2021;27(9):1048–63. DOI: 10.1111/cns.13659.</mixed-citation><mixed-citation xml:lang="en">Wang H., Lv J. J., Zhao Y., Wei H. L., Zhang T. J., Yang H. J., Chen Z. N., Jiang J. L. Endothelial genetic deletion of CD147 induces changes in the dual function of the blood-brain barrier and is implicated in Alzheimer’s disease. CNS Neuroscience &amp; Therapeutics. 2021;27(9):1048–63. DOI: 10.1111/cns.13659.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kong Y., Liu C., Zhou Y., Qi J., Zhang C., Sun B., Wang J., Guan Y. Progress of RAGE Molecular Imaging in Alzheimer’s Disease. Frontiers in Aging Neuroscience. 2020;12:227. DOI: 10.3389/fnagi.2020.00227.</mixed-citation><mixed-citation xml:lang="en">Kong Y., Liu C., Zhou Y., Qi J., Zhang C., Sun B., Wang J., Guan Y. Progress of RAGE Molecular Imaging in Alzheimer’s Disease. Frontiers in Aging Neuroscience. 2020;12:227. DOI: 10.3389/fnagi.2020.00227.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
